These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9226008)

  • 21. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients.
    Vecchio SD; Ciarmiello A; Potena MI; Carriero MV; Mainolfi C; Botti G; Thomas R; Cerra M; D'Aiuto G; Tsuruo T; Salvatore M
    Eur J Nucl Med; 1997 Feb; 24(2):150-9. PubMed ID: 9021112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Scintimammography with 99mTc-sestamibi as a complementary diagnostic technique.
    Torkzad MR
    Acta Radiol; 2001 May; 42(3):345. PubMed ID: 11419397
    [No Abstract]   [Full Text] [Related]  

  • 23. Local recurrence of breast cancer demonstrated on 99mTc-MIBI scintigraphy.
    Katayama N; Inoue Y; Ichikawa T; Harada M; Itoh T; Shimoyamada K; Ikeda M; Tsukune Y; Yoshikawa K
    Radiat Med; 1999; 17(5):389-91. PubMed ID: 10593293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 99mTc-MIBI scintigraphy as a functional method for the evaluation of multidrug resistance in breast cancer patients.
    Sergieva SB; Timcheva KV; Hadjiolov ND
    J BUON; 2006; 11(1):61-8. PubMed ID: 17318954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What can we expect from MDR breast cancer imaging with sestamibi?
    Palmedo H
    J Nucl Med; 2002 Apr; 43(4):526-30. PubMed ID: 11937597
    [No Abstract]   [Full Text] [Related]  

  • 26. Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression.
    Moretti JL; Azaloux H; Boisseron D; Kouyoumdjian JC; Vilcoq J
    Eur J Nucl Med; 1996 Aug; 23(8):980-6. PubMed ID: 8753690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer.
    Mubashar M; Harrington KJ; Chaudhary KS; Lalani el-N; Stamp GW; Sinnett D; Glass DM; Peters AM
    J Nucl Med; 2002 Apr; 43(4):519-25. PubMed ID: 11937596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 99mTc-sestamibi uptake and histological malignancy grade in invasive breast carcinoma.
    Danielsson R; Sánchez-Crespo A; Pegerfalk A; Grabowska H; Larsson SA; Boné B; Aspelin P
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):662-6. PubMed ID: 12616323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary osteogenic sarcoma of breast detected on Tc-99m MIBI scintigraphy and Tc-99m MDP skeletal scintigraphy.
    Yang JG; Li CL; Hao RR; Zou LF
    Ann Nucl Med; 2008 Jan; 22(1):79-82. PubMed ID: 18250991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Role of 99mTC-Sestamibi in the diagnosis of breast cancer. Report on 100 cases].
    Fliquete Peris MV; Giménez Climent J; Vázquez Forner C; Más Arcas C; Vázquez Albaladejo C
    Rev Esp Med Nucl; 1999 Dec; 18(6):436-41. PubMed ID: 10611570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MBI: M(I)BI agonistes or a new chapter?
    Brenner RJ
    Breast J; 2007; 13(1):1-2. PubMed ID: 17214786
    [No Abstract]   [Full Text] [Related]  

  • 32. [Differentiation of benign and malignant palpable breast masses using 99mTc-MIBI imaging].
    He J; Li Y; Su J
    Hunan Yi Ke Da Xue Xue Bao; 1997; 22(3):226-8. PubMed ID: 9868120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Complementary scintigraphic examinations (99mTc-MDP, 99mTc-MIBI and Octreoscan) in breast neoplasm assessment].
    Stefănescu C; Chossiere L; Rusu V; Meignan M
    Rev Med Chir Soc Med Nat Iasi; 1996; 100(3-4):165-8. PubMed ID: 9455458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 99mTc sestamibi scintimammography. Screening mammographic non-palpable suspicious breast lesions: preliminary results.
    Bekiş R; Derebek E; Balci P; Koçdor MA; Değirmenci B; Canda T; Durak H
    Nuklearmedizin; 2004 Feb; 43(1):16-20. PubMed ID: 14978536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic accuracy of 99mTc-sestamibi breast imaging: multicenter trial results.
    Khalkhali I; Villanueva-Meyer J; Edell SL; Connolly JL; Schnitt SJ; Baum JK; Houlihan MJ; Jenkins RM; Haber SB
    J Nucl Med; 2000 Dec; 41(12):1973-9. PubMed ID: 11138681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of late chest wall recurrence of breast carcinoma during Tc-99m sestamibi parathyroid scintigraphy.
    Conrad GR; Sloan DA; Sinha P
    Clin Nucl Med; 2003 May; 28(5):408-9. PubMed ID: 12702942
    [No Abstract]   [Full Text] [Related]  

  • 37. Three patients with bilateral breast tumors examined by technetium-99m-sestamibi scintimammography.
    Ohta H; Kosumi T; Kitai T; Yamamoto S; Ukikusa M; Awane H; Shintaku M
    Ann Nucl Med; 1997 Aug; 11(3):259-62. PubMed ID: 9310176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of 99mTc-sestamibi scintimammography and dynamic MR imaging as adjuncts to mammography in the diagnosis of breast cancer.
    Boné B; Wiberg MK; Szabó BK; Szakos A; Danielsson R
    Acta Radiol; 2003 Jan; 44(1):28-34. PubMed ID: 12630995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tc-99m tetrofosmin in breast carcinoma and axillary lymph node metastases: a comparative study with Tc-99m MIBI.
    Akçay MN; Akin Y; Karabağ B; Ozcan O; Oren D
    Clin Nucl Med; 1997 Dec; 22(12):832-4. PubMed ID: 9408644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tc-99m sestamibi exam finds niche in breast Dx.
    Chen EM; Khalkhali I; Cutrone JA; Diggles LE; Mishkin F
    Diagn Imaging (San Franc); 1997 Aug; 19(8):61-5. PubMed ID: 10169379
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.